Patents Assigned to Novartis Corporation
  • Patent number: 6096749
    Abstract: The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0,R is one or more substituents selected from halogen, alkyl, trifluoromethyl and alkoxy; andR.sub.1 and R.sub.2 are each independently of the other alkyl, or phenyl that is unsubstituted or substituted by halogen, trifluoromethyl, alkyl or by alkoxy, it also being possible for one of the two radicals R.sub.1 and R.sub.2 to be hydrogen, or R.sub.1 and R.sub.2 together form an alkylene chain having from 2 to 5 carbon atoms that is unsubstituted or substituted by alkyl;or salts thereof. Compounds of formula I inhibit protein kinases, for example the tyrosine protein kinase of the receptor for the epidermal growth factor, EGF.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: August 1, 2000
    Assignee: Novartis Corporation
    Inventors: Peter Traxler, Pascal Furet, Wolfgang K.-D. Brill
  • Patent number: 6083881
    Abstract: Compounds of formula (I) ##STR1## in which the substituents W, R.sub.100, R.sub.101 and R.sub.102 are as defined 1; and the pyrazole N-oxides, salts, complexes and stereoisomer of the compounds of (I) have good pre- and post-emergence selective herbicidal properties. The preparation compounds and their use as herbicidal active compounds are described.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: July 4, 2000
    Assignee: Novartis Corporation
    Inventors: Kurt Nebel, Hans-Georg Brunner, Georg Pissiotas
  • Patent number: 6072035
    Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 6, 2000
    Assignees: Novartis Corporation, Tanox Biosystems, Inc.
    Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
  • Patent number: 6068853
    Abstract: A delivery mechanism and device for the passive periodic release of a drug or an active ingredient which avoids the need for external power sources and/or electronic controllers. By taking advantage of oscillating chemical systems, one can change the state, i.e. the pH, of a solution, a drug, enhancer or solubilizer resulting in oscillating the ability of an active ingredient to be delivered transdermally. The pH of a solution can be oscillated over a range of pH values from 2 to 10 by the reduction and oxidation (redox) reactions of salts, such as permanganates, iodates, sulfates, chlorates, or bromates. Upon activation, the delivery system conditions begin to oscillate and with it, the delivery of the active agent oscillates.
    Type: Grant
    Filed: October 13, 1995
    Date of Patent: May 30, 2000
    Assignee: Novartis Corporation
    Inventors: Steven Andrew Giannos, Steven Minh Dinh, Bret Berner
  • Patent number: 6066447
    Abstract: Oligonucleotides of the formula: 5'(U).sub.n -3' in which U is an identical or different radical of a natural or a synthetic nucleoside and n is a number from 2 to 200 comprising at least one structural unit of two consecutive nucleosides wherein one of the nucleotides is substituted in the 2'-position or wherein the nucleotides are substituted differently in their 2'-position and wherein the backbone is modified.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: May 23, 2000
    Assignee: Novartis Corporation
    Inventors: Alain De Mesmaeker, Adrian Waldner, Jacques Lebreton, Marc-Olivier Bevierre, Catherine Lesueur
  • Patent number: 6066718
    Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.
    Type: Grant
    Filed: September 27, 1993
    Date of Patent: May 23, 2000
    Assignees: Novartis Corporation, Tanox Biosystems, Inc.
    Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
  • Patent number: 6066596
    Abstract: A herbicidal synergistic composition, comprising, besides customary inert formulation auxiliaries, a compound of formula I ##STR1## and a synergistically active amount of at least one active ingredient selected from among the compounds of formula II ##STR2## and of formula III ##STR3## and of formula V ##STR4##
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: May 23, 2000
    Assignee: Novartis Corporation
    Inventors: Jean Louis Allard, Manfred Hudetz
  • Patent number: 6057306
    Abstract: The invention relates to a method of treating the navicular disease in horses, which comprises treating the navicular disease in horses with an effective amount of at least one compound of formula (I), ##STR1## wherein R.sub.1 is hydrogen, hydroxy, amino or halogen, and R.sub.2 is hydrogen, halogen or a radical which is bound through C, N, S or O, or of a C.sub.1 -C.sub.4 tetraalkyl ester thereof, each in the free form or in the form of the salt and/or in the hydrate form; to a compound of formula (I) for use in a method of treating the navicular disease, to a composition for use in a method of treating the navicular disease, which comprises one or more than one compound of formula (I), as well as to the use of a compound of formula (I) for the preparation of a veterinary composition for treating the navicular disease.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: May 2, 2000
    Assignee: Novartis Corporation
    Inventors: Alan Martin Wilson, Allen Edward Goodship, Jonathan Green
  • Patent number: 6057430
    Abstract: The present invention relates to a folding process for the preparation of biologically active, dimeric TGF-.beta. (Tranforming Growth Factor type .beta.)-like protein.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: May 2, 2000
    Assignee: Novartis Corporation
    Inventor: Nico Cerletti
  • Patent number: 6054454
    Abstract: The present invention relates to the use of compounds of formula ##STR1## wherein A is an unsubstituted or mono- to tetrasubstituted, aromatic or non-aromatic, monocyclic or bicyclic heterocyclic radical, where one to two of the substituents of A can be selected from the group consisting of halo-C.sub.1 -C.sub.3 alkyl, cyclopropyl, halocyclopropyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl, halo-C.sub.2 -C.sub.3 alkenyl, halo-C.sub.2 -C.sub.3 alkynyl, halo-C.sub.1 -C.sub.3 alkoxy, C.sub.1 -C.sub.3 alkylthio, halo-C.sub.1 -C.sub.3 alkylthio, allyloxy, propargyloxy, allylthio, propargylthio, haloallyloxy, haloallylthio, cyano and nitro, and one to four of the substituents of A can be selected from the group consisting of C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and halogen; R is hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl; and X is N--NO.sub.
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: April 25, 2000
    Assignee: Novartis Corporation
    Inventors: Hariolf Schmid, Ernst Hess
  • Patent number: 6047495
    Abstract: Spraying tubes (20 . . . ) through each of which a plurality of spraying holes are perforated along the longitudinal axis of each tube are placed in prescribed positions upper than feces boards (10 . . . ) of henhouses; and the spraying tubes (20 . . . ) are connected to agent-supplying means for supplying an agent such as a tank, a pump, etc. and airsupplying means for supplying compressed air such as a compressor, etc. The spraying holes make an angle not smaller than 5 degrees and not greater than 90 degrees as measured downward from the horizontal plane at the time of spraying an agent, in order to make it possible to spray the agent to feces boards (10 . . . ) and feces floor (12). The eggs of pests such as housefly and the like laid on the feces adhering to the feces boards and feces floor can efficiently and certainly be controlled.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: April 11, 2000
    Assignee: Novartis Corporation
    Inventors: Syunji Matsumura, Isao Takada, Toshiaki Mima, Kazuo Fukui
  • Patent number: 6048824
    Abstract: Compounds of formula (I), wherein A is an unsubstituted or substituted aromatic or non-aromatic, monocyclic or bicyclic heterocyclic radical wherein a ring nitrogen atom may have been replaced by a group ##STR2## R.sub.1 is hydrogen or C.sub.1 -C.sub.3 alkyl; R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl; R.sub.3 is hydrogen, an unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl group, or C(.dbd.O)--R.sub.5, R.sub.5 is C.sub.1 -C.sub.4 alkyl C.sub.1 -C.sub.4 alkoxy, an unsubstituted or substituted phenyl, phenoxy or benzyloxy group, or N(R.sub.6).sub.2, each R.sub.6, independently of the other, is hydrogen, C.sub.1 -C.sub.4 alkyl or unsubstituted or substituted phenyl, X is CH--NO.sub.2, N--CN or N--NO.sub.2 and n is from 1 to 3, in free form or in salt form, and, where appropriate, tautomers of those compounds and the salts thereof, can be used as agrochemical active ingredients and can be prepared in a manner known per se.
    Type: Grant
    Filed: November 22, 1995
    Date of Patent: April 11, 2000
    Assignee: Novartis Corporation
    Inventors: Peter Maienfisch, Jozef Gonda, Olivier Jacob, Laurenz Gsell
  • Patent number: 6022871
    Abstract: Compounds of the formula ##STR1## in which A is an unsubstituted or mono- to tetrasubstituted, aromatic or non-aromatic, monocyclic or bicyclic heterocyclic radical, where one to two of the substituents of A can be selected from the group consisting of halo-C.sub.1 -C.sub.3 alkyl, cyclopropyl, halocyclopropyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl, halo-C.sub.2 -C.sub.3 alkenyl, halo-C.sub.2 -C.sub.3 alkynyl, halo-C.sub.1 -C.sub.3 alkoxy, C.sub.1 -C.sub.3 alkylthio, halo-C.sub.1 -C.sub.3 alkylthio, allyloxy, propargyloxy, allylthio, propargylthio, haloallyloxy, haloallylthio, cyano and nitro, and one to four of the substituents of A can be selected from the group consisting of C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and halogen;R is hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl; andX is N--NO.sub.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: February 8, 2000
    Assignee: Novartis Corporation
    Inventors: Peter Maienfisch, Laurenz Gsell
  • Patent number: 6002013
    Abstract: Compounds of the formula I ##STR1## and disulfides thereof and salts thereof are important intermediate products for the preparation of compounds having a microbicidal and plant-immunizing action, of the formula III ##STR2## In the compounds of the formulae I and III: X is halogen,n is 0, 1, 2 or 3;Z is CN, CO--A or CS--A,A is hydrogen, halogen, OR.sub.1, SR.sub.2 and N(R.sub.3)R.sub.4 ;R.sub.1 to R.sub.4 are hydrogen, a substituted or unsubstituted, open-chain, saturated or unsaturated hydrocarbon radical containing not more than 8 carbon atoms, a substituted or unsubstituted cyclic, saturated or unsaturated hydrocarbon radical containing not more than 10 carbon atoms, substituted or unsubstituted benzyl or phenethyl, a substituted or unsubstituted alkanoyl group containing not more than 8 carbon atoms, a substituted or unsubstituted benzoyl group or a substituted or unsubstituted heterocyclyl radical; or R.sub.3 and R.sub.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: December 14, 1999
    Assignee: Novartis Corporation
    Inventors: Walter Kunz, Beat Jau
  • Patent number: 5985921
    Abstract: Compounds of the formula ##STR1## in which n, q, A, X, G, Y, Z, R, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7 and R.sub.9 are as defined in claim 1, and, where appropriate, E/Z isomers, E/Z isomer mixtures and/or tautomers thereof, in each case in the free form or in an agrochemically suitable salt form, can be used as agrochemical active compounds and can be prepared in a manner known per se.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: November 16, 1999
    Assignee: Novartis Corporation
    Inventors: Saleem Farooq, Stephen Trah, Hugo Ziegler, Rene Zurfluh, Alfons Pascual, Henry Szczepanski, Roger Graham Hall
  • Patent number: 5981582
    Abstract: When used in admixture with mancozeb, chlorothalonil, a copper salt, folpet, fluazinam or cymoxanil (it being possible for the latter to be used also together with one of the other five components), metalaxyl having a high R-enantiomer content of more than 70% by weight, or pure R-metalaxyl, exhibits a markedly increased fungicidal action against plant diseases as compared with a similar mixture in which metalaxyl is used in the form of the racemate.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: November 9, 1999
    Assignee: Novartis Corporation
    Inventors: Cosima Nuninger, John Edward Nicholas Goggin, Dino Sozzi
  • Patent number: 5977332
    Abstract: Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each independently of the other hydrogen or a protecting group, orR.sub.1 has those meanings andR.sub.2 is a radical forming a phosphorus-containing nucleotide bridge group;B is a purine or pyrimidine radical or an analogue thereof; andR.sub.3 is OH, or F, and oligonucleotides that comprise those nucleosides are described.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: November 2, 1999
    Assignee: Novartis Corporation
    Inventor: Pierre Martin
  • Patent number: 5972698
    Abstract: The present invention relates to novel inhibitors of human tryptase, to their isolation from leeches, to nucleotide sequences encoding the novel inhibtor molecules or fragments thereof, to vectors containing the coding sequence thereof, to host cells transformed with such vectors, to the recombinant production of the inibitors, to pharmaceutical compositions containing the novel inhibitor molecules, and to their use in diagnosis and therapy.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: October 26, 1999
    Assignees: Novartis Corporation, UCP Gen-Pharma AG
    Inventors: Hans Fritz, Christian Sommerhoff
  • Patent number: 5969116
    Abstract: Compounds of the formula ##STR1## are described wherein R.sub.1 and R.sub.2 are each independently of the other hydrogen or a protecting group, orR.sub.1 has those definitions andR.sub.2 is a radical forming a phosphorus-containing nucleotide bridge group;B is a purine or pyrimidine radical or an analogue thereof; andR.sub.3 is a radical of formula Ia, Ib or Ic ##STR2## wherein R.sub.4 is hydrogen, C.sub.1 -C.sub.21 alkyl, C.sub.2 -C.sub.21 alkenyl, C.sub.2 -C.sub.21 alkynyl or --C(.dbd.O)-alkyl;R.sub.5 is hydrogen, C.sub.1 -C.sub.10 alkyl, --CH.sub.2 --O--R.sub.6 or a radical of formula Ib;R.sub.6 is hydrogen, C.sub.1 -C.sub.22 alkyl, C.sub.3 -C.sub.21 alkenyl, or partially or completely fluorine-substituted C.sub.1 -C.sub.10 alkyl or --[(CH.sub.2).sub.2 --O].sub.m --R.sub.7 ;R.sub.7 is hydrogen or C.sub.1 -C.sub.21 alkyl;Z is --(CH.sub.2).sub.p -- or --(CH.sub.2 --CH.sub.2 --O).sub.q --CH.sub.2 CH.sub.2 --, it being possible for Z in the case of --CH.sub.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 19, 1999
    Assignee: Novartis Corporation
    Inventor: Pierre Martin
  • Patent number: 5965592
    Abstract: Compounds of the formula ##STR1## and their salts, in which R.sub.1, is a C.sub.1 -C.sub.7 aliphatic hydrocarbon radical; X.sub.1 is --CO; X.sub.2 is a divalent aliphatic hydrocarbon radical which comprises an ethyl group and an alkylene of 2 to 6 carbon atoms; R.sub.2 is hydroxy, carboxy or alkoxycarbonyl in which alkoxy is from 1 to 7 carbon atoms; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl or 5-tetrazolyl; and the rings A and B independently of one another are otherwise unsubstituted; can be prepared in a known manner and may be used as active ingredients for medicaments.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: October 12, 1999
    Assignee: Novartis Corporation
    Inventors: Peter Buhlmayer, Franz Ostermayer, Tibur Schmidlin